Akkermansia: The microbe reshaping healthy longevity

Akkermansia muciniphila is now one of the most studied microbes in human nutrition—not because it’s fashionable, but because controlled trials keep pointing to clinically relevant effects. Danone’s Jan Knol, Gokul Swaminathan and Akkermansia pioneer Willem M. de Vos explain what makes this next‑generation biotic different, what the evidence says so far, and what may come next for microbiome science and future foods.

For years, “microbiome and gut health” was framed mainly as digestion. In parallel, “longevity” focused on muscle maintenance and frailty, while “anti‑inflammatory” talk often stayed stuck on vitamins. Those angles aren’t wrong—but they’re incomplete. They don’t explain why people with similar diets can age differently, or which levers we can realistically pull to shape how we age.

Our recent publication in Nature Medicine studies pasteurized Akkermansia muciniphila Mucᵀ in weight maintenance. It’s just one area where Akkermansia may influence health. This paper joins more than 30,000 scientific publications referencing Akkermansia across metabolic health, obesity, diabetes, and gut‑barrier biology.

What’s changing now is evidence quality: a new wave of human studies —from early pioneers at Wageningen University and UC Louvain to teams at Maastricht University and Danone R&I—lets us move beyond cautious “association” and more towards intervention and causality.

Recent findings link Akkermansia to muscle strength in older adults, metabolic health, and aspects of immune regulation. And because its ability to be stimulated by polyphenol‑rich foods common in Mediterranean diets, it connects nutrition, lifestyle, and healthy ageing in a fresh way.

Ageing doesn’t just change our muscles and metabolism—it changes our inner ecosystem, too. The gut microbiome shifts in composition and function, influenced by how we eat and move and how our immune system behaves. Diversity often declines, beneficial microbes can become harder to find, and older adults can differ more from each other “microbiome‑wise” than younger people do.

A few well-studied shifts help explain why. With age:

• The mucus layer protecting the gut lining can thin, 
• Digestion and transit time may slow and 
• The immune system becomes less precise—sometimes drifting into chronic, low‑grade inflammation. 

Add real‑world factors like less varied diets, medications and less exercise, and you have a recipe for losing the microbial balance in the gut. 

The good news: this isn’t destiny. Nutrition, movement and targeted microbiome‑supporting strategies can help maintain the resilience of the gut over time.

Age‑related loss of muscle strength (sarcopenia) can erode our reserves long before it shows up as falls, higher health risks or loss of independence. This decline can begin in our 30s and 40s, which is why “muscle ageing” has gone mainstream. 

Advice typically focuses on exercise and protein—which are foundational—but tends to ignore a key question: why do some people hold onto their strength more easily than others?

Could our gut and its residents provide part of the answer? Existing research only provides a hint about pasteurized Akkermansia and muscle strength, but it does give us an exciting new angle. Maybe long-term strength isn't only about feeding muscle but about supporting the gut ecosystem that helps regulate inflammation and metabolism in the background. 

Exercise and protein still matter. But diet and activity also correlate with higher gut Akkermansia levels—suggesting a reinforcing loop rather than a one‑off health hack.

For researchers, the gut–muscle link matters for a bigger reason: the gut barrier and low‑grade inflammation don’t just influence muscles. They can shape how tissues across the body age—quietly, cumulatively, and long before symptoms appear.

Ageing shows up in different ways in different parts of the body. Chronic, low‑grade inflammation—“inflammaging”—is quite common. It can be driven by ageing cells, less precise immune “brakes,” and more background inflammatory signals. Over time, it can lead to lower resilience and higher risk of age‑related conditions, including metabolic disorders.

As one of the body’s biggest interfaces with the outside world, the gut plays a central role in ageing. And when the intestinal barrier starts to weaken, microbial fragments may pass more easily into the bloodstream—often described as “leaky gut.” This is increasingly recognised as a contributor to systemic inflammation and inflammaging.

That’s why gut barrier strength has become a focal point in healthy‑longevity research.

Akkermansia muciniphila lives in the mucus layer lining the intestine—right where the gut barrier interacts with the immune system. Akkermansia is linked to mucus renewal, tight‑junction function (the seal between gut cells), and immune balance – and its population tends to decline with age.

One detail makes Akkermansia unusual: unlike many familiar probiotics, it may not need to be alive to have an effect. In fact, pasteurisation preserves key structural components of the bacterium (including its outer membrane protein, Amuc_1100) that interact with receptors in the gut.

Research suggests pasteurized (non-viable) Akkermansia muciniphila may support healthy‑ageing pathways in a few connected ways:

• It may help strengthen gut‑barrier integrity by supporting tight‑junction proteins and reducing permeability.
• Because it doesn’t need to colonise the gut to work, it may be a practical option for older populations where tolerability and compatibility matter.
• It offers formulation advantages: high stability (no cold chain), consistent dosing, and predictable effects independent of colonisation status.

The red thread is barrier function. Akkermansia lives at the gut lining; when that lining is well supported, fewer inflammatory signals leak into circulation. When it’s compromised, low‑grade inflammation can rise—and that’s where the healthy‑ageing conversation gets real. Recent findings from our Nature Medicine study add another layer to this picture, showing that pasteurized A. muciniphila Mucᵀ was associated with immune signaling changes, a dampening of inflammatory tone, and increased mitochondrial energy metabolism in adipose tissue.

A reassuring point is that we have different options to introduce and sustain our guts in general and specifically Akkermansia. Healthy diets, such as the Mediterranean diet, seem to support this live microbe, but irrespective of diet, pasteurized Akkermansia munciniphila Mucᵀ can help, because it does not depend on colonizing the gut to do its work.  

Our recent Nature Medicine publication on pasteurized Akkermansia muciniphila Mucᵀ reported signals including better weight‑loss maintenance in the intervention group and anti‑inflammatory signatures, as well as increased mitochondrial energy metabolism, in fat tissue.

These results add to a broader pattern: next generation microbes can have measurable, clinically relevant effects. They also reinforce a theme in microbiome science – and nutrition more broadly: context matters. Baseline biology, diet, and lifestyle can shape what you respond to—and how strongly.

Akkermansia is helping redefine what “microbiome support” can mean—from metabolism to healthy ageing, and from barrier function to immune signalling. The most compelling part of the story isn’t the headline – it’s that independent studies keep circling the same idea: the gut lining isn’t just plumbing. It’s a key controller that helps set the scene for whole‑body health.

Want to go deeper? The peer-reviewed sources below are a good starting point. We’ll keep sharing what Danone R&I teams and academic collaborators learn as the field moves from intriguing associations to measurable interventions.

Jan Knol, Senior Director, Gut Health, Immunology & Microbiome Research, Life Sciences & Innovation, Medical & Nutritional Sciences, Danone

Gokul Swaminathan, Director, Biotics New Growth Spaces, Life Sciences & Innovation, Medical & Nutritional Sciences, Danone

Willem M de Vos, Distinguished Professor Emeritus, Wageningen University; discovered Akkermansia and co founded The Akkermansia Company 

• Wageningen/UCLouvain lineage (de Vos & Cani)
• 2019 Nature Medicine proof of concept trial
• 2025 Cell Metabolism colonization and clinical improvement trial
• New Maastricht–Danone R&I Nature Medicine publication on pasteurized Mucᵀ ’s impact on weight loss maintenance and insulin sensitivity. 
• [pmc.ncbi.nlm.nih.gov], [frontiersin.org]
• [pmc.ncbi.nlm.nih.gov] 
• Suenaert, P. et al. (2026) ‘Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels’, Gut Microbes, 18(1). doi: 10.1080/19490976.2026.2690689.

Akkermansia muciniphila Mucᵀ is one of the best‑documented next‑generation microbes, with growing mechanistic and clinical evidence. EFSA has evaluated pasteurized A. muciniphila Mucᵀ under the Novel Food framework and concluded it is part of normal human gut microbiota and non‑toxin producing; pasteurisation addresses viability concerns while preserving key structures. Early human supplementation studies in metabolic syndrome also found pasteurized forms to be well tolerated, with signals across insulin sensitivity, inflammation markers, and lipid profiles—helping establish the “postbiotic” concept.